%0 Journal Article
%T Discontinuation of Peritoneal Dialysis after Late Initiation of Eculizumab in a Case of Familial Atypical Hemolytic-Uremic Syndrome: A Case Report
%A C¨¢ndido D¨ªaz Rodr¨ªguez
%A Daniel Novoa Garc¨ªa
%A Giannina Elena Garc¨ªa Rodr¨ªguez
%A Manuel Fidalgo D¨ªaz
%A Rafael Alonso Valente
%A Teresa Cordal Mart¨ªnez
%A Vanesa Becerra Mosquera
%A Yanina Garc¨ªa Marcote
%J Archive of "Case Reports in Nephrology and Dialysis".
%D 2017
%R 10.1159/000457950
%X Atypical hemolytic-uremic syndrome is caused by a thrombotic microangiopathy and manifests itself with hemolytic anemia, thrombocytopenia, and organ ischemia. Its etiology is a mutation affecting the genes encoding for proteins of the complement system. Early treatment with eculizumab (8.6 months from the moment of presentation), a humanized monoclonal antibody against complement, is shown to be effective in controlling symptoms and reversing organ damage. We present a patient with a mutation not previously described in the literature. Late treatment with eculizumab resulted in a good therapeutic response, eliminating the need for peritoneal dialysis
%K Atypical hemolytic-uremic syndrome
%K Eculizumab
%K Mutation
%K Complement inactivating agents
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465702/